Delays in the work-up and definitive management of patients with prostate cancer are common, with logistics of additional work-up after initial prostate biopsy, specialist referrals, and psychological reasons being the most common causes of delays. During the COVID-19 pandemic and the subsequent surges, timing of definitive care delivery with surgery or radiotherapy has become a topic of significant concern for patients with prostate cancer and their providers alike. In response, recommendations for the timing of definitive management of prostate cancer with radiotherapy and radical prostatectomy were published but without a detailed rationale for these recommendations. While the COVID-19 pandemic is behind us, patients are always asking the question: "When should I start radiation or undergo surgery?" In the absence of level I evidence specifically addressing this question, we will hereby present a narrative review to summarize the available data on the effect of treatment delays on oncologic outcomes for patients with localized prostate cancer from prospective and retrospective studies.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-024-00876-2DOI Listing

Publication Analysis

Top Keywords

prostate cancer
20
definitive management
12
localized prostate
8
patients prostate
8
covid-19 pandemic
8
timing definitive
8
prostate
6
cancer
5
delayed definitive
4
management localized
4

Similar Publications

Objective: To examine the role and diagnostic potential of miR-421 in prostate cancer (PCa).

Methods: Expression data and clinical information for miR-421 were obtained from the TCGA and Genotype-Tissue Expression (GTEx) databases. Experimental validation was performed at the cellular, blood, and tissue levels to confirm miR-421 expression and its association with clinicopathological features.

View Article and Find Full Text PDF

Prostate cancer (PCa) is the second leading cause of cancer-related deaths among American men. The development of metastatic castration resistant PCa (mCRPC) is the current clinical challenge. Antiandrogens such as Enzalutamide (ENZ) are commonly used for CRPC treatment.

View Article and Find Full Text PDF

Androgen receptor (AR) signaling is a target in prostate cancer therapy and can be treated with non-steroidal anti-androgens (NSAA) including enzalutamide, and apalutamide for patients with advanced disease. Metastatic castration-resistant prostate cancer (mCPRC) develop resistance becomes refractory to therapy limiting patient overall survival. Darolutamide is a novel next-generation androgen receptor-signaling inhibitor that is FDA approved for non-metastatic castration resistant prostate cancer (nmCRPC).

View Article and Find Full Text PDF

Temporally and Spatially Controlled Age-Related Prostate Cancer Model in Mice.

Bio Protoc

January 2025

Department of Structural and Cellular Biology, Tulane University, New Orleans, LA, USA.

The initiation and progression of prostate cancer (PCa) are associated with aging. In the history of age-related PCa research, mice have become a more popular animal model option than any other species due to their short lifespan and rapid reproduction. However, PCa in mice is usually induced at a relatively young age, while it spontaneously develops in humans at an older age.

View Article and Find Full Text PDF

This study aims to study how gold nanoparticles (AuNPs) function in the recruitment and polarization of tumor-associated macrophages (TAMs) in hormone-sensitive prostate cancer (HSPC) and castration-resistant prostate cancer (CRPC). Phorbol ester (PMA)-treated THP-1 cells were cocultured with LNCaP or PC3 cells to simulate TAMs. Macrophage M2 polarization levels were detected using flow cytometry and M2 marker determination.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!